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Introduction
The association of alcohol with liver damage has
been well established. During the early stages, the
liver is enlarged owing to severe fatty change. Inflam-
matory changes and hepatocyte necrosis with the
alcoholic hyaline of Mallory and variable extents of
liver fibrosis are characteristic pathological features
in alcoholic liver disease (1). During the 1980s, liver
diseases with very similar pathological findings,
which latently progress to liver cirrhosis, were recog-
nized in nonalcoholics. Typical examples were
observed as an extremely frequent complication of
jejunoileal bypass surgery for morbidly obese
patients and as a rare adverse reaction to a few medi-
cines (2, 3). Since this disease entity was defined
pathologically irrespective of etiology, both fatty liver
hepatitis and nonalcoholic steatohepatitis (NASH)
have been used to describe “the pathological and clin-
ical features of non-alcoholic disease of the liver asso-
ciated with the pathological features most common-
ly seen in alcoholic liver disease itself ” (4).
Recently, NASH has become the second or third
most common liver disease in outpatient hepatology
practice in North America (2). This has led to a debate
as to whether hepatic steatosis, which is easily defined
from the liver/spleen ratio of computed tomography
values in Hounsfield units less than 0.9 (5), is an
“innocent bystander or guilty party” in NASH (6).
Because liver diseases have not been widely appreciat-
ed as life-threatening complications of obesity, hepat-
ic steatosis has been regarded as an innocent
bystander of NASH. However, evidence implying obe-
sity is a risk for liver diseases has recently been accu-
mulated. For example, liver cirrhosis is approximate-
ly sixfold more prevalent in obese individuals than in
the general population, and obesity increases the risk
of liver cirrhosis (7), and, in addition, gradual pro-
gression from hepatic steatosis to NASH and eventu-
ally to cirrhosis is supported by epidemiologic find-
ings (8). Thus, a consensus about NASH was recently
provided; namely, that hepatic steatosis is regarded as
a risk of NASH and that a “second hit” capable of
inducing necrosis, inflammation, and fibrosis in the
liver is required for NASH, as most patients with
hepatic steatosis do not develop liver cirrhosis (2, 9,
10). An exposure to endotoxin/bacterial lipopolysac-
charides, iron overload, and accumulation of long
chain and very long chain fatty acids (VLCFAs) were
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Hepatic steatosis is a frequent complication in nonobese patients with breast cancer treated with
tamoxifen, a potent antagonist of estrogen. In addition, hepatic steatosis became evident sponta-
neously in the aromatase-deficient (ArKO) mouse, which lacks intrinsic estrogen production. These
clinical and laboratory observations suggest that estrogen helps to maintain constitutive lipid
metabolism. To clarify this hypothesis, we characterized the expression and activity in ArKO mouse
liver of enzymes involved in peroxisomal and mitochondrial fatty acid b -oxidation. Northern analy-
sis showed reduced expression of mRNAs for very long fatty acyl-CoA synthetase, peroxisomal fatty
acyl-CoA oxidase, and medium-chain acyl-CoA dehydrogenase, enzymes required in fatty acid b -oxi-
dation. In vitro assays of fatty acid b -oxidation activity using very long (C24:0), long (C16:0), or medi-
um (C12:0) chain fatty acids as the substrates confirmed that the corresponding activities are also
diminished. Impaired gene expression and enzyme activities of fatty acid b -oxidation were restored
to the wild-type levels, and hepatic steatosis was substantially diminished in animals treated with
17 b -estradiol. Wild-type and ArKO mice showed no difference in the binding activities of the hepat-
ic nuclear extracts to a peroxisome proliferator response element. These findings demonstrate the
pivotal role of estrogen in supporting constitutive hepatic expression of genes involved in lipid 
b -oxidation and in maintaining hepatic lipid homeostasis.
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suggested as candidates for the “second hit” (2, 7, 9).
In the 1990s, adjuvant tamoxifen became a standard
treatment for women with early breast cancer. A 5-year
treatment of adjuvant tamoxifen reduced the recurrence
risk of estrogen receptor–positive cancer by 50% (11).
Moreover, the same adjuvant trials showed a 40% reduc-
tion in the risk of cancer recurrence in the opposite
breast and in the ductal carcinoma in situ (12, 13).
These studies may further promote adjuvant tamoxifen,
as 5-year treatment of tamoxifen for breast cancer
undoubtedly outweighs the risks of the adverse effects.
However, it was reported that rapidly progressive hepat-
ic steatosis among nonobese nondiabetic breast cancer
patients treated with tamoxifen was known to induce
NASH and liver cirrhosis on rare occasions (8, 14–17).
The frequency of progressive hepatic steatosis had
increased to 36% (18, 19), and more than ten patients in
our clinic were shown by liver biopsy to have tamoxifen-
induced NASH. A body mass index (BMI; kg/m2)
greater than 23 was a significant risk factor for tamox-
ifen-induced hepatic steatosis (19). As hepatic steatosis
is suggested as a risk factor of NASH, it is important to
elucidate the mechanisms involved in the rapid pro-
gression of hepatic steatosis during adjuvant tamoxifen.
Because tamoxifen is a potent antagonist of estro-
gen, and estrogen is believed to be profoundly involved
in hepatic lipid metabolism (20), this suggested that
tamoxifen could suppress hepatic lipid b -oxidation
and accelerate lipid accumulation in hepatocytes. To
clarify this, we developed aromatase-deficient (ArKO)
mice lacking intrinsic estrogen production, because
aromatase is a key enzyme in estrogen synthesis (21,
22). We investigated constitutive expression of PPAR-
a and fatty acid–metabolizing enzymes in peroxisome,
mitochondria, and microsomes of ArKO mice. Here,
we show that hepatocellular fatty acid b -oxidation is
impaired in ArKO mice and that the impairment in
mitochondrial and peroxisomal fatty acid b -oxidation
is restored to a wild-type level with supplementation
of 17 b -estradiol. These findings clarify the fundamen-
tal role of estrogens in constitutive expression of fatty
acid–metabolizing enzymes to maintain hepatic lipid
homeostasis, and implicate estrogen receptor-signal-
ing pathways in the control of constitutive hepatic
lipid metabolism.
Methods
Mice. The aromatase gene (cyp 19 gene) was disrupted
by homologous recombination (23). In brief, an 87-bp
fragment located within exon 9 of cyp 19 gene in E14-
1 cells (embryonic stem cell; ES cell) was replaced with
a neomycin resistance gene derived from pMC1-neo.
Selected ES cells were microinjected into the C57BL/6J
blastocytes to generate chimeric mice. Chimeric male
mice were then mated with C57BL/6J female mice to
generate mice heterozygous for the mutation. Het-
erozygous mice were mated to obtain aromatase null
(ArKO) mice because of the infertility of homozygous
males and females. Genotypes of mice were determined
by PCR using genomic DNA isolated from tail tips.
ArKO (Ar–/–) male mice aged 6 months and their wild-
type male siblings (Ar+/+) fed with a CE-2 diet (Clea
Japan, Tokyo, Japan) were used in the present study.
ArKO mice were divided into two groups: the Ar–/–
group was nontreated, and the Ar–/– + E2 group was
subcutaneously supplemented with 7.5 m g/mouse of
17b -estradiol (E2) every 4 days for the first 3 weeks after
birth and once a week with 0.75 m g/mouse thereafter.
Animal care and experiments were carried out in accor-
dance with institutional animal care regulations.
Light microscopic observations. Liver tissues were rou-
tinely fixed in 10% phosphate-buffered formalin (pH
7.4), embedded in paraffin, and sectioned for hema-
toxylin-and-eosin staining. The degree of hepatic
steatosis was classified into four grades according to
the distribution pattern of the fat vesicles as follows: 0
= no or few fat droplets in the lobules; 1= a few fat
droplets in the lobules; 2 = fat droplets restricted to
zone 3; 3 = fat droplets in zones 3 and 2; 4 = numerous
fat droplets in zones 3 and 2.
Analysis of mRNA expression for enzymes involved in fatty
acid b -oxidation. mRNA analysis was performed by
Northern blotting. Total liver RNA was obtained from
fresh liver using the acid guanidinium thiocyanate-phe-
nol-chloroform extraction method. RNA was separated
on 1% agarose gel and transferred to a nylon membrane.
The membranes were incubated with 32P-labeled cDNA
probes and analyzed on a Fuji system analyzer (Fuji
Photo Film, Tokyo, Japan). The cDNA used for North-
ern blotting included catalase, very long fatty acyl-CoA
synthetase (VLACS), peroxisomal acyl-CoA oxidase
(AOX), medium-chain acyl-CoA dehydrogenase
(MCAD), CYP2E1, CYP4A1 (20), GAPDH, and b -actin.
Changes in mRNA levels were estimated by densito-
metric scanning of autoradiograms and analyzed by
NIH Image software (version 1.52; National Institutes
of Health, Bethesda, Maryland, USA) to show a relative
ratio to the findings in the Ar+/+ group.
Fatty acid b -oxidation activity. Fatty acid b -oxidation
activity was measure as described previously (24). In
brief, fresh liver was homogenized in four volumes of
0.25 M sucrose containing 1 mM EDTA in a Potter-
Elvehjem homogenizer (Ikemoto Rika, Tokyo, Japan)
using a tight-fitting Teflon pestle. Homogenate (1–10
mg) was incubated with the assay medium in 0.2 mL
of 150 mM KCl, 10 mM HEPES (pH 7.2), 0.1 mM
EDTA, 1 mM potassium phosphate buffer (pH 7.2), 5
mM malonate, 10 mM MgCl2, 1 mM carnitine, 0.15%
BSA, 5 mM ATP, and 50 m M each fatty acid (105 cpm
for radioactive substrates) (55 mCi/mmol; American
Radiolabeled Chemicals, St. Louis, Missouri, USA):
[1-14C]tetracosanoic acid (C24:0), [1-14C]palmitic acid
(C16:0), or [1-14C]lauric acid (C12:0). The reaction
was run for 30 minutes at 25°C and stopped by the
addition of 0.2 mL of 0.6 N perchloric acid. The mix-
ture was centrifuged at 2,000 g for 10 minutes, and
the unreacted fatty acid in the supernatant was
removed using 2 mL of n-hexane with three extrac-
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tions. Radioactive degradation products in the water
phase were counted. Fatty acid b -oxidation activity
was expressed as nanomolars per minute per liver. In
some experiments using [1-14C]palmitic acid, KCN, a
potent inhibitor of the mitochondrial respiratory
chain, was added to the assay medium to inhibit
potent mitochondrial activity.
Lipid analysis. Lipid composition of the livers (n = 3)
and total plasma lipids (n = 5) were analyzed using gas
chromatograph equipped with a glass capillary column.
Three parameters of the VLCFAs in sphingomyelin
from plasma, the ratio of hexacosanoic acid (C26:0) to
docosanoic acid (C22:0), of pentacosanoic acid (C25:0)
to C22:0, and of tetracosanoic acid (C24:0) to C22:0,
were analyzed by chemical ionization mass spectrome-
try combined with capillary gas chromatography (25).
Preparation of nuclear extracts and electrophoretic mobili-
ty shift assay. Nuclear extracts from the liver were pre-
pared according to the method of Jiang and Eberhardt
(26). The protein concentration of the nuclear extracts
was determined by the method of Lowry et al. (27). The
peroxisome proliferator response element (PPRE) of
AOX (28) was synthesized (5 ¢ -CCAGGACAAAGGT-
CACG-3 ¢ ) and subcloned at the SmaI site of a pUC118
plasmid. The EcoRI-BamHI fragments containing the
PPRE were end labeled with [ a -32P]dCTP using the
Klenow fragment. The radiolabeled fragments were
purified by spin column chro-
matography and used as a probe
in the assay. The 32P-labeled probe
of 65 pg ( ~ 46 cpm/pg) was incu-
bated at 20°C for 20 minutes in 20
m L of a mixture containing 10 mM
HEPES-KOH (pH 7.9), 100 mM
KCl, 1 mM EDTA, 1 mM dithio-
threitol, 3 mM MgCl2, 5% (vol/vol)
glycerol, 50 m g/mL poly(dI-dC), 20
m g of protein from the nuclear extracts, and various
amounts of competitor DNAs. The unlabeled probe
and C/EBP binding element were used as specific and
nonspecific competitor DNAs, respectively. After incu-
bation, the mixtures were subjected to electrophoresis
in a 4% nondenaturing polyacrylamide gel in a Tris-
glycine buffer (50 mM Tris base, 380 mM glycine, and
2 mM EDTA [pH 8.5]). The gel was then dried and
autoradiographed. PPAR- a content was estimated by
densitometric scanning and analyzed by NIH Image
software (version 1.52).
Statistic analysis. Data were analyzed using Student’s t
test or Wilcoxon signed rank test.
Results
Light microscopic observation. The growth of ArKO mice in
the first 2 months after birth is similar to that of their
wild-type siblings. Thereafter, they gradually accumu-
lated abdominal fat in an estrogen-free condition, and
hepatic steatosis became evident spontaneously,
although there was a slight variation in the severity. As
shown in Figure 1, liver cells in zones 3 and 2 (cen-
trilobular and intermediate zones in the lobules)
showed marked microvesicular steatosis in ArKO mice.
Liver cells with features of microvesicular steatosis did
not contain any large fat droplets, but the cytoplasm of
some liver cells filled with numerous fat droplets had
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Figure 1
Light micrographs of livers of ArKO
mice (a and b) and ArKO mice sup-
plemented with 17b -estradiol (c and
d). (a) Zones 2 and 3 of liver lobules
are composed of liver cells with
marked fatty changes rimmed with
narrower zone 1 areas of normal
appearing liver cells. (b) Higher mag-
nification of liver cells in zone 3. The
enlarged cytoplasm is filled with
numerous fat droplets, although
microvesicular features are promi-
nent. (c) In marked contrast to the
findings in ArKO mice livers (a and b),
liver tissues show the normal struc-
ture. (d) Higher magnification of a
perivenular portion in c. All liver cells
are normal in appearance. c, central
vein; p, portal tract. Scale bar = 200
m m (a and c) and 50 m m (b and d).
Hematoxylin-and-eosin staining.
Table 1
Grades of hepatic steatosis in three groups of mice
Grade Description Ar+/+ group Ar–/– group Ar–/– + E2 group
n = 10 n = 10 n = 10
0 No or few fat droplets in the lobules 8 0 8
1 A few fat droplets in the lobules 1 0 2
2 Fat droplets restricted to zone 3 1 0 0
3 Fat droplets in zone 3 and 2 0 3 0
4 Numerous fat droplets in zone 3 and 2 0 7 0
both small and large fat droplets. However, liver cells in
zone 1 (periportal) remained intact. Such a zonal dif-
ference of steatosis within the liver lobule was very clear.
Hepatic steatosis was not observed in their wild-type
siblings and supplementation of 17b -estradiol retrieved
ArKO mice from massive hepatic steatosis (Table 1). No
necroinflammatory lesions were present in any group. 
mRNA analysis. To clarify whether estrogen is
involved in hepatic lipid metabolism, constitutive
mRNA expression of hepatic peroxisomal (catalase,
VLACS, AOX), mitochondrial (MCAD), and microso-
mal (CYP2E1 and CYP4A1) enzymes were analyzed by
Northern blots in the Ar+/+, Ar–/–, and Ar–/– + E2
groups as shown in Figure 2. Constitutive mRNA
expression of mitochondrial MCAD (0.15 ± 0.05) and
of three peroxisome-associated enzymes, VLACS (0.35
± 0.05), AOX (0.19 ± 0.04), and catalase (0.17 ± 0.03),
were significantly lower in the Ar–/– group than that in
the Ar+/+ and Ar–/– + E2 group, whereas microsomal
CYP4A1 mRNA expression (1.73 ± 0.09), which is well
known to be induced by PPAR- a stimulation (29), was
significantly higher in the Ar–/– group (P = 0.043 in
Wilcoxon signed rank test).
Fatty acid b -oxidation activity. Compared with the Ar+/+
group, the basal levels of total fatty acid b -oxidation
activity in the Ar–/– group were lower using [1-
14C]C24:0 (3.26 ± 0.15 vs. 0.73 ± 0.08 nmol/min/liver;
P < 0.001), [1-14C]C16:0 (66.0 ± 3.5 vs. 19.8 ± 2.9
nmol/min/liver; P < 0.001) or [1-14C]C12:0 (13.4 ± 1.7
vs. 3.9 ± 0.1 nmol/min/liver; P < 0.001) as the sub-
strates (Figure 3). They reverted very close to the wild-
type level by supplementation with 17b -estradiol (2.81
± 0.14 nmol/min/liver [P < 0.001]; 54.4 ± 2.5
nmol/min/liver [P < 0.001]; and 10.0 ± 0.5
nmol/min/liver [P < 0.001], respectively).
Electrophoretic mobility shift assay. The nuclear extracts
(20 m g protein) prepared from the liver of Ar+/+ (lanes
2–8), ArKO (lanes 9–11), or ArKO + E2 (lanes 12–14)
mice were incubated with the 32P-labeled probe in the
absence of the competitor DNA (lanes 2, 9, and 12) or
in the presence of 25-fold molar excess (lanes 3 and 6),
50-fold molar excess (lanes 4 and 7), 100-fold molar
excess (lanes 5, 8, 10, 11, 13, and 14) of the unlabeled
probe (lanes 3–5, 10, and 13) or the C/EBP binding ele-
ment (lanes 6–8, 12, and 14) (Figure 4). These findings
show that PPAR- a expression was not impaired in
ArKO mice and ArKO + E2 mice.
Lipid analysis. Hepatic lipid content in the Ar–/– group
was significantly higher than that in the Ar+/+ and Ar–/– +
E2 group (Table 2). Relative ratio of lipid content in Ar+/+
mice versus Ar–/– mice varied from 5.5 to 14.0 in the liver
and from 0.75 to 3.5 in the plasma (Figure 5). Three
parameters of VLCFAs in plasma sphingomyelin were
also similar in these three groups. The C26:0/C22:0 ratio,
C25:0/C22:0 ratio, and C24:0/C22:0 ratio were 0.022,
0.045, and 1.038, respectively, in the Ar+/+ group. They
were 0.021, 0.033, and 0.930 in the Ar–/– group and 0.025,
0.045, and 0.746 in the Ar–/– + E2 group (Figure 6).
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Figure 2
Northern blot analysis of gene expression in ArKO mice. Total cellu-
lar RNA was isolated from the liver samples of ArKO mice treated or
not treated with 17b -estradiol (E2+, E2–) and their wild-type siblings
(WT). Probes of peroxisomal and mitochondrial enzymes essential
for b -oxidation were used in the assay. Equal amounts of total RNA
were applied in the analysis.
Figure 3
Impaired hepatic fatty acid b -oxidation activity in ArKO mice. Per-
oxisomal b -oxidation capacity was assessed using tetracosanoic acid
(C24:0) as the substrate, and mitochondrial b -oxidation capacity,
using palmitic acid (C16:0) and lauric acid (C12:0). The bars repre-
sent the mean ± SD from at least six samples in each group. AStatis-
tically significant difference (P < 0.001) compared with the value
obtained with the wild-type group (Ar+/+) and the ArKO mice sup-
plemented with 17 b -estradiol group (Ar–/– + E2).
Discussion
In the present study, we demonstrated that the dis-
ruption of the cyp 19 gene encoding aromatase
resulted in massive hepatic steatosis (Figure 1) as
observed in tamoxifen-induced hepatic steatosis in
human (17, 18). Inflammatory changes were absent
in ArKO mice with massive hepatic steatosis,
although tamoxifen-induced hepatic steatosis in
human occasionally developed NASH (8, 17–19).
This strongly supports the idea that hepatic steatosis
is not sufficient and that a “second hit” to hepatic
steatosis is needed for the development of NASH (2,
9, 10). During adjuvant tamoxifen therapy, the plas-
ma ferritin concentration was increased only in
patients with hepatic steatosis (19). This suggests
that oxidative stress and subsequent lipid peroxida-
tion induced by excessive free iron could deteriorate
mitochondrial function of hepatocytes and induce
hepatocyte necrosis and inflammatory changes in
tamoxifen-induced NASH.
Biochemical analysis of ArKO liver revealed that
mRNA expression of enzymes involved in peroxiso-
mal and mitochondrial b -oxidation were markedly
suppressed in ArKO mice (Figure 2). AOX, VLACS,
and MCAD have an essential role in fatty acid b -oxi-
dation of hepatocytes; i.e., VLACS and AOX are
enzymes involved in the first two steps of peroxiso-
mal b -oxidation by which VLCFAs are exclusively
metabolized, and MCAD is an enzyme catalyzing a
rate-limiting step in the mitochondrial oxidation of
medium-chain fatty acyl-thioesters produced by per-
oxisomal b -oxidation of long-chain fatty acids (20,
30). Such suppression of gene expression induced by
the lack of estrogen, however, was not due to the gen-
eralized impairment of gene expression, because the
expression of a gene such as cyp 4A1 was enhanced in
the same liver.
Consistent with these findings, b -oxidation activi-
ties of C24:0, C16:0, and C12:0 were lower in ArKO
mice than in wild-type mice (Figure 3). Supplemen-
tation with 17 b -estradiol restored these defects and
resulted in reverting the hepatic lipid content close
to the levels of wild-type mice (Table 2). Furthermore,
it was reported that tamoxifen, a potent antagonist
of estrogens, frequently induced hepatic steatosis
without significant changes in BMI among nonalco-
holic, nondiabetic, and nonobese women with breast
cancer (17–19). These clinical and laboratory obser-
vations in human and ArKO mice suggest that the
estrogen receptor–mediated signaling pathway plays
important roles in basal hepatic lipid homeostasis.
PPAR- a is another well-established nuclear mole-
cule maintaining homeostasis in hepatocellular fatty
acid uptake and utilization (20, 29–32). It binds to
PPRE and regulates peroxisome proliferation.
Although studies on PPAR- a –deficient mice have
demonstrated that loss of the receptor did not affect
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Figure 4
Electrophoretic mobility shift assays. The nuclear extracts pre-
pared from the liver of wild-type siblings (Ar+/+) (lanes 2–8), KO
(Ar–/–) (lanes 9–11) or KO + E2 (Ar–/– supplemented with 17 b -
estradiol) (lanes 12–14) are incubated with the 32P-labeled PPRE
in the absence of the competitor DNA (lanes 2, 9, and 12) or in
the presence of 25-fold molar excess (lanes 3 and 6), 50-fold
molar excess (lanes 4 and 7), 100-fold molar excess (lanes 5, 8,
10, 11, 13, and 14) of the unlabeled PPRE (lanes 3–5, 10, and 13)
or of the C/EBP binding element (lanes 6–8, 12, and 14).
Figure 5
Increased lipid content of the liver and plasma in ArKO mice: a rel-
ative ratio of lipid content in Ar–/– mice versus in Ar+/+ mice. 1:
C12:0, 2: C14:0, 3: C16:0, 4: C16:1w7, 5: C18:0, 6: C18:1w9, 7:
C18:2w6, 8: C18:3w6, 9: C18:3w3, 10: C20:0, 11: C20:1w9, 12:
C20:2w6, 13: C20:3w9, 14: C20:3w6, 15: C20:4w6, 16: C20:5w3,
17: C22:0, 18: C22:1w9, 19: C22:4w6, 20: C22:5w3, 21: C22:6w3,
22: C24:0, and 23: C24:1w9.
constitutive gene expression of enzymes involved in
peroxisomal b -oxidation (20), we assessed the bind-
ing activities of the hepatic nuclear extracts to a syn-
thetic PPRE. The PPRE binding activity was similar
in wild-type and ArKO mice (Figure 4), implying that
estrogen is not essential in maintaining constitutive
PPAR- a expression in hepatocyte nuclei. Therefore,
this suggested that administration of peroxisome
proliferator could improve hepatic lipid b -oxidation
in estrogen deficiency. We administrated bezafibrate
to ArKO and succeeded in treatment of severe hepat-
ic steatosis (data not shown). With this finding, we
administrated bezafibrate to treat tamoxifen-
induced NASH, and, fortunately, severe hepatic
steatosis was improved dramatically (18). These
findings revealed an important finding that consti-
tutive PPAR- a expression in hepatocyte nuclei is not
sufficient enough to salvage defective constitutive
lipid b -oxidation in estrogen deficiency, but admin-
istration of peroxisome proliferator can activate
PPAR- a –mediated signaling pathways even in estro-
gen deficiency and can improve hepatic steatosis.
Although the roles for maintaining constitutive
lipid metabolism under normal physiological con-
ditions are largely unknown, peroxisome prolifera-
tors are known to alter the expression of estrogen-
metabolizing enzymes (33). This suggests that
constitutive gene expression of the enzymes essential
for fatty acid b -oxidation under normal physiologi-
cal conditions might be orchestrated by an estrogen
receptor–mediated signaling pathway in cooperation
with a PPAR- a –mediated signaling pathway.
Long chain fatty acids and VLCFAs are assumed to
be an important factor in the pathogenesis of NASH
in AOX-deficient mice (2), and reduced mRNA
expression of AOX and VLACS was observed in ArKO
mice with normal levels of VLCFAs. We suggest that
the ArKO mouse could be a useful animal model to
investigate the mechanisms involved in tamoxifen-
induced NASH among patients with breast cancer.
1824 The Journal of Clinical Investigation | June 2000 | Volume 105 | Number 12
Table 2
Lipid analysis of the liver and plasma in ArKO mice
Liver (n = 3) Plasma (n = 5)
Ar +/+ (m g/liver) Ar–/– (m g/liver) Ar–/– + E2( m g/liver) Ar+/+ (m g/mL) Ar–/– (m g/mL) Ar–/– + E2 ( m g/mL)
Lauric acid (C12:0) 2.2 16.0 2.8 0.6 0.5 0.6
Myristic acid (C14:0) 32.2 346.8 36.1 5.4 6.8 5.1
Palmitic acid (C16:0) 7,069.2 47,576.0 6,584.7 280.0 460.5 277.0
Palmitoleic acid (C16:1w7) 172.6 2,250.8 165.9 28.6 35.6 27.2
Stearic acid (C18:0) 4,707.2 27,178.8 4,816.0 116.5 198.2 124.9
Oleic acid (C18:1w9) 1,900.6 16,058.8 2,138.1 214.8 332.2 201.4
Linoleic acid (C18:2w6) 5,038.4 31,909.2 4,798.2 350.1 827.1 346.4
g -Linoleic acid (C18:3w6) 62.8 413.2 58.7 4.7 8.1 4.4
Linoleic acid (C18:3w3) 67.2 493.2 70.1 7.9 27.9 7.2
Arachidonic acid (C20:0) 20.6 224.0 20.0 1.3 3.8 1.1
Eicosenoic acid (C20:1w9) 41.8 434.8 45.1 3.2 9.6 2.9
Eicosadienoic acid (C20:2w6) 75.0 634.8 68.7 2.8 8.1 3.0
Eicosatrienoic acid (C20:3w9) 19.0 266.8 20.3 1.2 0.9 1.1
di-Homo- g -linoleic acid (C20:3w6) 414.6 3,845.2 394.5 15.0 30.6 16.3
Arachidonic acid (C20:4w6) 3,435.2 19,034.8 3,331.2 133.9 200.7 129.0
Eicosapentaenoic acid (C20:5w3) 400.4 3,749.2 386.6 33.5 39.3 33.7
Docosanoic acid (C22:0) 71.2 688.0 69.4 2.9 3.2 2.8
Erucic acid (C22:1w9) 6.0 45.2 5.7 > 1.0 1.8 > 1.0
Docosatetraenoic acid (C22:4w6) 38.4 240.0 40.9 1.5 3.4 1.6
Docosapentaenoic acid (C22:5w3) 125.4 1,397.2 133.1 7.5 14.7 7.3
Docosahexaenoic acid (C22:6w3) 3,140.2 25,368.0 2,937.6 97.8 190.3 85.5
Tetracosanoic acid (C24:0) 83.4 728.0 84.0 3.5 3.8 3.3
Nervonic acid (C24:1w9) 187.0 1410.8 174.8 11.7 10.6 12.1
Total 27,110.6 184,309.6 26,382.5 1,324.4 2,417.7 1,293.9
Hepatic and plasma lipid content in ArKO (Ar–/–) mice were clearly higher than that in ArKO mice treated with 17 b -estradiol (Ar–/– + E2) and their wild-
type siblings (Ar+/+).
Figure 6
Serum VLCFA content. Three parameters of VLCFAs in plasma
sphingomyelin are similar in ArKO treated with 17 b -estradiol
(ArKO + E2) or in those not treated with 17 b -estradiol (ArKO)
and their wild-type siblings (Ar+/+).
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